Artiva Biotherapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 27, 2026, 8:30 a.m. ETView on SEC.gov
Results of operations and financial condition · Costs of exit or disposal activities · Financial statements and exhibits
AI summary, unreviewedArtiva Biotherapeutics halts AlloNK development, cuts workforce by 94% and explores strategic alternatives; preliminary cash $319.1 million
8-KSept. 11, 2026, 4:21 p.m. ETView on SEC.gov
Departure/appointment of directors or officers · Submission of matters to a vote of security holders · Financial statements and exhibits
8-KAug. 6, 2026, 4:09 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits